150 related articles for article (PubMed ID: 27031008)
21. [Radiosensitization induced by vemurafenib].
Ducassou A; David I; Delannes M; Chevreau C; Sibaud V
Cancer Radiother; 2013; 17(4):304-7. PubMed ID: 23810304
[TBL] [Abstract][Full Text] [Related]
22. Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAF
Wada F; Hiramoto N; Yamashita D; Hara S; Furukawa Y; Ishii J; Nagata K; Nannya Y; Ogawa S; Ishikawa T
Am J Hematol; 2021 Aug; 96(8):E295-E298. PubMed ID: 33971044
[No Abstract] [Full Text] [Related]
23. Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.
Ruan GJ; Goyal G; Shah MV; Cohen-Aubart F; Amoura Z; Straetmans N; Benameur N; Haroche J; Go RS;
Pancreas; 2021 Jan; 50(1):e6-e8. PubMed ID: 33370037
[No Abstract] [Full Text] [Related]
24. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma.
Cohen PR; Kurzrock R
Dermatol Online J; 2014 Jan; 20(1):21241. PubMed ID: 24456945
[TBL] [Abstract][Full Text] [Related]
25. Detection of anti-neutrophil cytoplasmic and antinuclear autoantibodies favouring misdiagnoses in 5 cases of Erdheim-Chester disease.
Özden F; Schinke S; Thorns C; Eckey T; Dalhoff K; Münte TF; Tronnier V; Humrich JY; Riemekasten G; Lamprecht P
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):176. PubMed ID: 29652657
[No Abstract] [Full Text] [Related]
26. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
[TBL] [Abstract][Full Text] [Related]
27. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
[TBL] [Abstract][Full Text] [Related]
28. A cytologic diagnosis of BRAF
Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary Erdheim-Chester disease successfully treated with vemurafenib.
Shen KN; Chang L; Niu N; Li J; Cao XX
Ann Hematol; 2024 Feb; 103(2):673-675. PubMed ID: 37924362
[No Abstract] [Full Text] [Related]
30. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra.
Killu AM; Liang JJ; Jaffe AS
Int J Cardiol; 2013 Sep; 167(5):e115-7. PubMed ID: 23659884
[No Abstract] [Full Text] [Related]
31. Long-term follow-up of mTOR inhibition for Erdheim-Chester disease.
Pegoraro F; Maniscalco V; Peyronel F; Westenend PJ; Hendriksz TR; Roperto RM; Palumbo AA; Sieni E; Romagnani P; van Bommel EFH; Vaglio A
Blood; 2020 May; 135(22):1994-1997. PubMed ID: 32299103
[No Abstract] [Full Text] [Related]
32. BRAF mutations in Erdheim-Chester disease.
Emile JF; Charlotte F; Amoura Z; Haroche J
J Clin Oncol; 2013 Jan; 31(3):398. PubMed ID: 23248255
[No Abstract] [Full Text] [Related]
33. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ
Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease.
Cao XX; Niu N; Sun J; Zhou DB; Li J
Ann Hematol; 2018 Jan; 97(1):185-187. PubMed ID: 28831599
[No Abstract] [Full Text] [Related]
35. [Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature].
Adam Z; Szturz P; Bučková P; Cervinková I; Koukalová R; Rehák Z; Krejčí M; Pour L; Zahradová L; Hájek R; Král Z; Mayer J
Vnitr Lek; 2012 Apr; 58(4):313-8. PubMed ID: 22559807
[TBL] [Abstract][Full Text] [Related]
36. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.
Tzoulis C; Schwarzlmüller T; Gjerde IO; Søfteland E; Neckelmann G; Biermann M; Haroche J; Straume O; Vintermyr OK
BMC Res Notes; 2015 Apr; 8():171. PubMed ID: 25926131
[TBL] [Abstract][Full Text] [Related]
37. Erdheim-Chester Disease With Cardiovascular Involvement and BRAF V600E Mutation.
Okamura K; Suematsu Y; Morizumi S; Kawata M; Dai Y; Yamakawa M; Ono M
Circ J; 2016 Jun; 80(7):1657-9. PubMed ID: 27296272
[No Abstract] [Full Text] [Related]
38. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease.
Cohen-Aubart F; Emile JF; Maksud P; Galanaud D; Idbaih A; Chauvet D; Amar Y; Benameur N; Amoura Z; Haroche J
Neurology; 2014 Sep; 83(14):1294-6. PubMed ID: 25171932
[No Abstract] [Full Text] [Related]
39. Vemurafenib as first-line therapy in
Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
